FDA Approves Dupilumab (Dupixent) for Eczema

Designated a breakthrough therapy, dupilumab spares patients with moderate to severe eczema from the need to resort to systemic immunosuppressants and the higher risks they pose.
FDA Approvals

http://ift.tt/2nevO3E